FirstWord belongs to a business group that forms one of the world’s largest healthcare knowledge networks. By tapping into its rich resources, FirstWord Dossier reports provide insight, analysis and the latest thinking on important trends and the most challenging issues affecting the pharmaceutical industry today. Highly-focused, relevant, up-to-date and actionable intelligence reports that deliver information vital for competitive advantage.

Page

The ROI of Orphan Drugs-- Ensuring optimal returns (2017)

By FirstWord Dossier | Healthcare | Dec 2017 | Page 0

Orphan drugs are at the forefront of medical science and offer a chance for the pharma industry to make a real difference to peoples lives; theres also the lure of....

USD 745 View Report

RCC [2017]: Bulletin #2

By FirstWord Dossier | Healthcare | Dec 2017 | Page 0

This edition presents key opinion leader (KOL) views on recent developments in the renal cell carcinoma (RCC) market. Topics covered include; the early halting of the CheckMate-214 trial and subsequent....

USD 1095 View Report

CAR-T Therapy in Haematological Malignancy: Update Bulletin #2

By FirstWord Dossier | Healthcare | Dec 2017 | Page 0

This edition presents leading US and EU key opinion leader (KOL) views on recent developments in the CAR-T therapy space. Topics covered include expert opinions on the FDA approvals of....

USD 1095 View Report

Colorectal Cancer: Update Bulletin #1

By FirstWord Dossier | Healthcare | Dec 2017 | Page 0

This edition presents the views and insights from three world leading key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the colorectal cancer....

USD 1095 View Report

Ulcerative Colitis: Update Bulletin #1

By FirstWord Dossier | Healthcare | Dec 2017 | Page 0

This edition presents key opinion leader (KOL) views on recent developments in the ulcerative colitis (UC) market. Topics covered include: Takeda and Portal Instruments announcing the production of a needle-free....

USD 1095 View Report